PR

Company presentation at LSX Nordic Congress 2021

From September 7-17 Isofol participated in LSX Nordic Congress, an opportunity for 1:1 meetings with Nordic life science executives focused on International Strategy, Investment, Partnering and Deal Making. See Isofol´s CEO, Jarl Ulf Jungnelius’ company presentation from the event below. LSX Nordic Congress 2021 – presentation >> For more information, please contact Isofol Medical AB

Company presentation at LSX Nordic Congress 2021 Read More »

Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin

GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the outcome of an advisory board meeting held to discuss the current status and ongoing strategy for the development of arfolitixorin, the company’s proprietary drug candidate being studied in the global pivotal Phase 3 AGENT study for advanced

Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin Read More »

Isofol Medical AB (publ) appoints Carnegie Investment Bank AB (publ) to Financial advisor

GOTHENBURG, Sweden, February 27, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), announced today that the company and the board have appointed Carnegie Investment Bank AB (publ) as financial advisor to explore a possible listing of the company’s shares at Nasdaq Stockholm main market within 12-18 months and to evaluate other strategic

Isofol Medical AB (publ) appoints Carnegie Investment Bank AB (publ) to Financial advisor Read More »

Isofol Reports All Employees Participate in Newly Created Share Warrant Program

GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that all senior executives and employees participated in Isofol’s share warrant program “2018” (series 2018/2022 and series 2018/2023). A total of 1,260,139 warrants with the right to subscribe for new shares in Isofol were acquired. Management and employees

Isofol Reports All Employees Participate in Newly Created Share Warrant Program Read More »

Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of Roger Tell, MD., PhD as Chief Scientific Officer (CSO) and Senior Vice President (SVP) of clinical development. Dr. Tell has more than a decade of experience as a clinical oncologist in addition to holding management

Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development Read More »

Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of Robert Marchesani as an advisor to its board of directors. Mr. Marchesani has nearly 30 years of experience in the life science industry, leading a variety of business activities including product development, global branding and

Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors Read More »

Scroll to Top